Related to Accelerating Scientific Breakthroughs Must Be Our Priority

• Barack to Business in 2009
  At least for the biotech sector, change is certainly here.
  
• Final Stimulus Package Provides $21.5B for Research
  Biggest winner seems to be the NIH, which will receive $8.5 billion for research grants.
  
• Biotech Industry Gears Up for Health Reform Push
  Don’t let innovation be forgotten, they urge.
  
• Obama Budget Greeted with Kudos Along with a Few Concerns
  While basic research is getting a boost, industry advocates point out that small biotech are still struggling.
  
• Opinion: Pathway for FOBs Should Balance Need for Competition and Need for Innovation
  Biotech industry should support innovations including those inherent in developing biosimilars, says James Bianco, M.D., principal founder, CEO, and director of Cell Therapeutics.
  
• Biotech and Generic Industries Lock Horns over Biosimilars
  Points of contention include data exclusivity, interchangeability, and clinical trial requirements.
  
• Supporters of hESC Research Ecstatic with President Obama’s Executive Order
  NIH guidelines will work for federally funded stem cells, but some say protocols are needed for all cell lines.
  
• Opinion—Regulatory Planning Key for Emerging Technology Companies
  Strategies formed early help keep investors and partners happy as well as create a smoother development path.
  
• Market Exclusivity—Paramount in Evaluating Target Companies
  The main related factors are relevant facts, freedom to operate, IP, third-party agreements, and regulatory exclusivity.
  
• While Grateful for Recovery Act Funds, Experts Stress the Importance of Continued Robust Funding
  Academia is now beginning to leverage the money, but tool companies are still waiting to feel the impact.
  
• The Underappreciated Cost-Saving Potential of Personalized Medicine in Health Reform Debate
  The current draft includes comparative effectiveness research but does not provide nearly as much funding as is needed for CER.
  
• Federal Circuit Holds that Methods of Optimizing Drug Efficacy Are Patentable
  Pending U.S. Supreme Court decision could further transform the standard for patentability of medical diagnostic claims.
  
• Opening Up the Lines of Communication at the Patent Office
  Changes to the count system, which tracks examiners’ workflow, grant them one more hour to conduct interviews.
  
• Part 1—The U.S. International Trade Commission and Intellectual Property
  Advantages of going to the ITC over U.S. courts include speedy resolutions and remedies that prohibit infringers from the entire U.S. market.
  
• Part 2—Tips for Biotech/Pharma Complainants and Respondents When Going to the ITC
  Going to the ITC provides needed tools like foreign discovery that are not available in a district court.